Apnimed (NASDAQ:APMD) Trading Up 7.7% – Should You Buy?

Posted by Geri Gentry on Sep 16th, 2026

Apnimed, Inc. (NASDAQ:APMD – Get Free Report) traded up 7.7% during mid-day trading on Wednesday . The company traded as high as $27.52 and last traded at $27.52. Approximately 165,956 shares were traded during trading, a decline of 53% from the average session volume of 349,963 shares. The stock had previously closed at $25.56.

Analysts Set New Price Targets

APMD has been the subject of several recent research reports. Wall Street Zen raised shares of Apnimed to a “hold” rating in a research report on Saturday, August 8th. Bank of America started coverage on Apnimed in a research note on Tuesday, August 25th. They set a “buy” rating and a $41.00 price target for the company. Lifesci Capital initiated coverage on Apnimed in a report on Tuesday, August 25th. They set an “outperform” rating and a $50.00 price objective for the company. Evercore began coverage on Apnimed in a research note on Tuesday, August 25th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald assumed coverage on Apnimed in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Apnimed has an average rating of “Moderate Buy” and an average target price of $50.33.

Check Out Our Latest Stock Analysis on APMD

Apnimed Stock Up 8.0%

Apnimed (NASDAQ:APMD – Get Free Report) last released its earnings results on Tuesday, September 8th. The company reported $0.51 earnings per share (EPS) for the quarter. The business had revenue of $12.08 million during the quarter. On average, sell-side analysts anticipate that Apnimed, Inc. will post -0.24 earnings per share for the current year.

Insiders Place Their Bets

In other Apnimed news, major shareholder Morningside Venture Investment acquired 312,500 shares of Apnimed stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the purchase, the insider directly owned 7,152,713 shares of the company’s stock, valued at $114,443,408. This trade represents a 4.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Apnimed Company Profile

(Get Free Report)

Apnimed Inc is a clinical-stage pharmaceutical company focused on developing oral medicines for sleep apnea. The company is working to provide pharmacologic alternatives to device-based treatments for patients with obstructive sleep apnea, a condition involving repeated interruptions in breathing during sleep.

Apnimed’s lead candidate is AD109, an investigational once-daily combination of atomoxetine and aroxybutynine. The therapy is designed to improve the activity of muscles that help keep the upper airway open during sleep.